Entry Point Capital, LLC Biocryst Pharmaceuticals Inc Call Options Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCRX
# of Institutions
278Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$158 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$155 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$92.3 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$70.7 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$68.8 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.45B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...